Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a note issued to investors on Monday. They presently have a $17.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 22.13% from the company’s current price.

Several other research firms also recently issued reports on VRX. BMO Capital Markets reaffirmed a “hold” rating and set a $15.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 27th. Deutsche Bank AG set a $19.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, July 17th. J P Morgan Chase & Co set a $10.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $35.00 target price on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $17.62.

Valeant Pharmaceuticals International (NYSE VRX) traded up 0.43% during mid-day trading on Monday, reaching $13.98. 668,362 shares of the company’s stock were exchanged. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $27.84. The firm’s market cap is $4.87 billion. The stock has a 50-day moving average of $14.39 and a 200-day moving average of $13.19.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The firm had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company’s revenue for the quarter was down 7.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.88) earnings per share. Analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/18/valeant-pharmaceuticals-international-inc-vrx-stock-rating-reaffirmed-by-hc-wainwright.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the acquisition, the director now directly owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.87% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gruss & Co. Inc. bought a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $104,000. Harbor Advisors LLC bought a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $110,000. NEXT Financial Group Inc lifted its position in shares of Valeant Pharmaceuticals International by 6.2% during the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after purchasing an additional 600 shares in the last quarter. Financial Architects Inc lifted its position in shares of Valeant Pharmaceuticals International by 10.5% during the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,000 shares in the last quarter. Finally, WMS Partners LLC bought a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $116,000. 50.47% of the stock is currently owned by institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.